Evotec's Milestone Math Fails to Move the Needle as Shares Hug Their 52-Week Low

Evotec shares drop 2.8% post-Plectonic partnership as Q2 revenue falls 19.2%, EBITDA loss widens, and 2026 guidance cut erodes investor faith.

The pattern has become painfully familiar for Evotec shareholders: a partnership announcement lands, the stock perks up for a session or two, and then the gravity of a deteriorating income statement pulls it straight back down. The latest iteration came last Wednesday, when the Hamburg-based drug discovery group unveiled a research collaboration with Plectonic Biotech targeting T-cell-activating approaches for solid tumors. The shares briefly jumped 5 percent before surrendering those gains and then some — they now sit 2.8 percent below the level seen before that announcement.

That fleeting enthusiasm underscores a deeper problem: the market's faith in Evotec's milestone-based business model has eroded badly since the company slashed its 2026 guidance in mid-July. At the current price of €3.20, the stock is barely 2 percent above its 52-week low of €3.14, touched just days ago on September 2. The distance from the November high of €7.75 — a 59 percent decline — tells the story of how quickly investor conviction evaporated.

The Numbers Behind the Skepticism

The final second-quarter and first-half figures, confirmed just over a week ago, did little to change the narrative. Group revenue fell 19.2 percent to €300.1 million in the first six months, while adjusted EBITDA swung from a minus €1.9 million loss a year earlier to a minus €42.7 million deficit. Management pointed to the "Horizon" transformation program as evidence that cost measures are being implemented on schedule, but the scale of the earnings deterioration has left analysts and investors questioning when the operational drag will ease.

Not every division is struggling. The Discovery & Preclinical Development (D&PD) unit posted a 28 percent jump in net revenue, and subsidiary Just–Evotec Biologics reports high capacity utilization and a broadening customer base. Yet these bright spots remain too small to offset weakness elsewhere in the group, and the market has taken notice: since the guidance confirmation, the stock has shed another 4.8 percent.

A Familiar Cycle of Disappointment

The Plectonic deal follows a similar announcement roughly a month ago, when Evotec launched an AI-powered drug discovery collaboration with Nasdaq-listed Odyssey Therapeutics focused on autoimmune and inflammatory diseases. That news also generated a brief pop — and then faded, with the shares down 7.4 percent since. Investors appear to be discounting the value of milestone payments when core financials are still contracting, a rational response to a business model whose economics depend on future success payments that have yet to materialize at scale.

Adding to the overhang, Camilla Macapili Languille departed the Supervisory Board on August 7, a resignation the company has not linked to operational performance but which has coincided with an 8.1 percent slide in the stock. An earlier downgrade from a research house, which included a sharp cut to the price target, has contributed another 8.7 percent of downside over a slightly longer window.

Technical Damage and the Road Ahead

The chart offers little comfort to holders. The shares trade 35 percent below their 200-day moving average of €4.94, a technical configuration that typically signals a firmly entrenched downtrend rather than a temporary dip. Year-to-date, the stock is down 41 percent, a decline that makes the confirmation of already-reduced guidance feel less like new information and more like an acknowledgment of reality.

Management has reiterated its full-year revenue target of €570 million to €610 million, first trimmed in July and now confirmed with the half-year results. That range represents the next meaningful checkpoint for a company trying to convince the market it has found a floor. Until the core numbers show convincing signs of stabilization, further collaboration announcements may continue to generate headlines — but, as the past month has demonstrated, they are unlikely to generate lasting share price momentum on their own.